Teacher: Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.
Teacher: Now, understand the problem? If you are still confused, see the following example:
"Although the story didn't cite the cost of appendectomy emergency or urgent surgery and we wish it had, we nonetheless will give it a satisfactory score because it at least cited what the editorial writer wrote, ""A secondary benefit is the savings to the hospital generated by minimizing staff and anesthesiologist presence late in the evening and during the wee hours of the morning."" As with our harms score above, although the story didn't give absolute numbers, in this case we think it was sufficient for it to report that ""The scientists found no significant difference among the groups in the patients' condition 30 days after surgery or in the length of their operation or hospital stay."" Although the story didn't give absolute numbers, in this case we think it was sufficient for it to report that ""The scientists found no significant difference among the groups in the patients' condition 30 days after surgery or in the length of their operation or hospital stay."" Despite running less than 300 words, this story did an adequate job in explaining the quality of the evidence, including pointing out limitations. No disease-mongering here. The story meets the bare minimum requirement for this criterion in that it at least cited what an editorial stated. The focus of the story was on a study comparing emergency appendectomy with surgery done up to 12 hours later or beyond. This is the whole focus of the story and one we applaud when it begins: ""Appendectomy is the most common emergency surgery in the world, but it doesn't have to be."" There were no claims made about the novelty of this research, and we may have wished for a bit more context on this. Nonetheless, the potential for guiding future care decisions was made clear. Not applicable. Given that the story only pulled excerpts from the journal article and the accompanying editorial, and didn't include any fresh quotes from interviews, we can't be sure of the extent to which it may have been influenced by a news release."
Solution: Some appendicitis cases may not require 'emergency' surgery
Reason: The paragraph mentions that "Appendectomy is the most common emergency surgery in the world, but it doesn't have to be." which is considered evidence for the output. Thus, the output is a valid claim.

Now, solve this instance: They said post-menopausal women who took the Novartis AG NOVN.VX drug Femara anywhere from one to seven years after finishing a five-year regimen of tamoxifen reduced the risk the cancer would come back by 63 percent. "What our results have shown for the first time in breast cancer treatment history is that taking an anti-estrogen anywhere along that line appears to have a dramatic reduction in the risk of recurrence," said Dr. Paul Goss of Massachusetts General Hospital, whose study appears in the Journal of Clinical Oncology. The drug, known generically as letrozole, cut the risk of cancer spreading to other areas of the body by 61 percent, and cut the risk that a tumor would develop in the unaffected breast by more than 80 percent. Letrozole belongs to a new class of breast cancer drugs known as aromatase inhibitors, which block the production of estrogen that can lead to cancer. It is recommended for use in women past menopause. The most widely used estrogen-blocking drug is tamoxifen, which was shown to cut the risk of cancer recurrence by close to 50 percent. But benefits of the pill, sold by AstraZeneca (AZN.L) under the brand Nolvadex and also sold generically, fall significantly after five years. Tamoxifen also raises the risk of death from strokes and endometrial cancer. But more than half of breast cancer recurrences and deaths occur five or more years after completing tamoxifen. "What is important for doctors and patients to recognize unfortunately is that the risk of recurrence of this type of breast cancer does not end at five years," Goss said in a telephone interview. "The risk continues and the benefit remains substantial of starting late on therapy," Goss said. Goss' findings are based on an analysis of 1,579 women who decided to switch to letrozole from a placebo after the trial was halted. Their results were compared to about 800 women who stayed on the placebo. Almost three years after the study ended, those who began letrozole had only a 2 percent risk of tumor recurrence, compared with almost 5 percent in those choosing no treatment. Goss said the findings were limited by the fact that women made the decision about whether they would take the drug or not. Nevertheless, he said the findings are strong and likely to change how women with breast cancer are treated. "The risk that hormone-dependent breast cancer will recur continues indefinitely, and our results imply that aromatase inhibition is effective whenever initiated," said Goss, who is also a professor at Harvard Medical School. He said the study looked at the effects of letrozole only, but said the results will likely apply to all aromatase inhibitors. Pfizer Inc (PFE.N) makes an aromatase inhibitor called exemestane, which it sells under the brand Aromasin, and AstraZeneca Plc (AZN.L) makes anastrozole, sold under the brand Arimidex. Another study in the journal showed that taking another exemestane soon after completing tamoxifen treatment reduced the risk of recurrence by 56 percent. Breast cancer is the second-leading cause of cancer death among U.S. women after lung cancer. It kills 500,000 people globally every year.
Student:
Femara Cuts Cancer Recurrence Even if Started Late.